Molecular Characterisation of Urothelial Bladder Cancer: Will it Improve Patient Care?

Erben P, Hartmann A, Bolenz C (2015)

Publication Type: Journal article

Publication year: 2015

Journal

Aktuelle Urologie Georg Thieme Verlag

Publisher: Georg Thieme Verlag

Book Volume: 46

Pages Range: 227-35

Journal Issue: 3

DOI: 10.1055/s-0035-1549992

Abstract

Urothelial bladder cancer is characterised by high recurrence and progression rates despite multimodal treatment. Only slight improvements have been achieved during the last decades. The current histopathological classification and clinical risk stratification tools are inaccurate. Hence, a better understanding of the tumour biology is essential for the improvement of patient care. The molecular characterisation of bladder cancer may be translated into useful diagnostic and predictive biomarkers. Many potential therapeutic targets have been identified such as FGFR3 (Fibroblast growth factor receptor 3), HER2 (human epidermal growth factor receptor 2) and PD1/PDL1 (programmed cell death-1). They need validation in clinical trials. We now review the molecular biology of urothelial bladder carcinoma and discuss clinical applications of biomarkers and targeted therapies.

Authors with CRIS profile

Arndt Hartmann Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie

Involved external institutions

Ruprecht-Karls-Universität Heidelberg DE Germany (DE)

How to cite

APA:

Erben, P., Hartmann, A., & Bolenz, C. (2015). Molecular Characterisation of Urothelial Bladder Cancer: Will it Improve Patient Care? Aktuelle Urologie, 46(3), 227-35. https://doi.org/10.1055/s-0035-1549992

MLA:

Erben, P., Arndt Hartmann, and C. Bolenz. "Molecular Characterisation of Urothelial Bladder Cancer: Will it Improve Patient Care?" Aktuelle Urologie 46.3 (2015): 227-35.

BibTeX: Download